JACARDI (Joint Action on CARdiovascular Diseases and Diabetes) is an EU initiative supporting 21 European countries in addressing the burdens of cardiovascular diseases (CVD) and diabetes at both individual and systemic levels.
The European Heart Network (EHN) actively contributes to the JACARDI Project through representation on the Strategic Advisory Board by EHN Board member Paola Santalucia and EHN CEO Birgit Beger. Additionally, EHN is engaged in Work Package 2 (WP2), focusing on communication efforts to ensure effective dissemination of project outcomes. EHN’s involvement supports the project’s goals by advising on current policy and public health priorities, as well as aiding in the dissemination of project findings to broaden engagement and impact across Europe.
Several EHN member organisations are actively participating in JACARDI:
The JACARDI project, active from November 2023 to October 2027, works to reduce chronic disease impacts with:
EHN actively supports the following JACARDI Work Packages, aligned with its mission to advocate for cardiovascular health:
While EU life expectancy has increased, the prevalence of chronic illnesses has grown, with 1 in 6 adults living with CVD and nearly 1 in 10 with diabetes. JACARDI aims to improve health outcomes and address health disparities across social groups and regions.
JACARDI collaborates with 76 partners from diverse sectors, operating in tandem with the WHO and European scientific organizations. The project leverages insights from past initiatives such as CHRODIS, Best-ReMaP, and JADECARE to build on successful health strategies.
Discover more about the JACARDI Project at jacardi.eu.
JACARDI has received funding from the EU4Health Programme 2021-2027 under Grant Agreement 101126953. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the grating authority can be held responsible for them